The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
CORONARY INTERVENTIONS
Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial
EuroIntervention 2016;12:e160-e166 published online e-edition June 2016. DOI: 10.4244/EIJ-D-15-00371
Michael Haude1*, MD, PhD; Raimund Erbel2, MD, PhD; Paul Erne3, MD, PhD; Stefan Verheye4, MD; Hubertus Degen1, MD; Paul Vermeersch4, MD; Neil Weissman5, MD; Francesco Prati6, MD; Nico Bruining7, MD, PhD; Ron Waksman5, MD; Jacques Koolen8, MD
1. Medical Clinic I, Städtische Kliniken-Neuss, Lukaskrankenhaus GmbH, Neuss, Germany; 2. Department of Cardiology, West German Heart Center Essen, Essen, Germany; 3. Cardiology Department, Luzerner Kantonsspital, Lucerne, Switzerland; 4. Department of Ca
Aims: Bioresorbable scaffolds were designed to overcome the limitations of permanent stents. In the BIOSOLVE-I study we aimed to assess the long-term safety and performance of a drug-elut